Prime Medicine, Inc. (PRME) stock
PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.84−0.35 (-8.35%)
Close on Nov 17, 2026Market cap $696.49MP/E –Yield –
Prime Medicine operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Prime Medicine's operating cash flow for the twelve months ending Jun 30, 2026 was -$156.05M. For fiscal 2025 it was -$162.56M. The highest annual figure on record is -$5.54M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$162.56M | – |
| FY2024 | Dec 31, 2024 | -$122.87M | – |
| FY2023 | Dec 31, 2023 | -$165.41M | – |
| FY2022 | Dec 31, 2022 | -$131.83M | – |
| FY2021 | Dec 31, 2021 | -$34.08M | – |
| FY2020 | Dec 31, 2020 | -$5.54M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$41.05M | – |
| Q1 FY2026 | Mar 31, 2026 | -$42.71M | – |
| Q4 FY2025 | Dec 31, 2025 | -$37.26M | -329.3% |
| Q3 FY2025 | Sep 30, 2025 | -$35.04M | – |
| Q2 FY2025 | Jun 30, 2025 | -$41.41M | – |
| Q1 FY2025 | Mar 31, 2025 | -$48.86M | – |
| Q4 FY2024 | Dec 31, 2024 | $16.25M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.91M | – |
| Q2 FY2024 | Jun 30, 2024 | -$45.49M | – |
| Q1 FY2024 | Mar 31, 2024 | -$67.71M | – |
| Q4 FY2023 | Dec 31, 2023 | -$43.86M | – |
| Q3 FY2023 | Sep 30, 2023 | -$39.17M | – |
| Q2 FY2023 | Jun 30, 2023 | -$40.82M | – |
| Q1 FY2023 | Mar 31, 2023 | -$41.56M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.71M | – |
| Q3 FY2022 | Sep 30, 2022 | -$30.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.22M | – |
| Q1 FY2022 | Mar 31, 2022 | -$50.79M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.19M | – |
See a number that looks wrong?